First-Line Systemic Therapy Selection in Unresectable Metastatic Colorectal Cancer

This segment focuses on practical decision-making for first-line systemic therapy in patients with unresectable, multi-organ mCRC, particularly those with left-sided, RAS/BRAF wild-type disease. Dr Parikh frames the discussion around ongoing controversies, including the use of triplet versus doublet chemotherapy, timing of anti-EGFR therapy, and balance between efficacy and quality-of-life considerations such as skin toxicity.

Panelists describe varied but overlapping practice patterns. Several faculty favor FOLFOXIRI plus bevacizumab for the majority of patients, citing strong efficacy data and a strategy focused on intensive induction followed by de-escalation to maintenance therapy. This approach is viewed as a way to maximize early disease control while preserving long-term tolerability. Patient age, functional status, and comorbidities factor heavily into decisions, with some clinicians adopting a more conservative approach in older patients.

For left-sided, RAS wild-type tumors, anti-EGFR–based therapy is acknowledged as an important option, though the necessity of administering it in the first line remains debated. Faculty reference data showing that many patients in bevacizumab-based arms never received subsequent anti-EGFR therapy, raising questions about sequencing and access rather than biologic necessity. Nonetheless, there is growing recognition that earlier anti-EGFR use may be advantageous, particularly if EGFR rechallenge strategies are anticipated later.

Quality of life emerges as a central theme. Panelists emphasize treatment holidays, maintenance strategies, and dose modifications to support long-term disease control while allowing patients to live well. Anti-EGFR toxicities, especially chronic skin and hand toxicity, are highlighted as meaningful burdens that warrant proactive management, dose adjustments, and breaks.

Overall, this segment underscores that first-line treatment selection in mCRC requires individualized balancing of biology, efficacy, sequencing opportunities, and patient-centered goals.